# Palmer Square Capital BDC Inc.: financial statements, quarterly

PSBD · NYSE · CIK 1794776 · [Other](/sectors/other.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/psbd.md) · [Financials](/companies/psbd/financials.md) · [Filings](/companies/psbd/filings.md) · [Insiders](/companies/psbd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/psbd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating income | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $m | [11.5](/filings/0001213900-23-085238.md) | [11.8 d](/filings/0001213900-24-017740.md) | [13.2](/filings/0001213900-24-040236.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [33.9](/filings/0000950170-24-121066.md) | [22.0 d](/filings/0001193125-26-073362.md) | [22.9](/filings/0000950170-25-064975.md) | [5.3](/filings/0000950170-25-103522.md) | [7.6](/filings/0001193125-25-265688.md) | [11.9 d](/filings/0001193125-26-073362.md) | [(8.4)](/filings/0001193125-26-207523.md) | [7.2](/filings/0001193125-26-333791.md) | [3.4](/filings/0001193125-25-265688.md) | [(5.3) d](/filings/0001193125-26-073362.md) | [(37.2)](/filings/0001193125-26-207523.md) | [8.5](/filings/0001193125-26-333791.md) |
| Diluted EPS | $ per share | [0.57](/filings/0000950170-24-121066.md) | not reported | [0.52](/filings/0000950170-25-064975.md) | [0.48](/filings/0000950170-25-103522.md) | [0.48](/filings/0001193125-25-265688.md) | not reported | [0.40](/filings/0000950170-25-064975.md) | [0.43](/filings/0000950170-25-103522.md) | [0.43](/filings/0001193125-25-265688.md) | not reported | not reported | not reported |
| Basic EPS | $ per share | [0.57](/filings/0000950170-24-121066.md) | not reported | [0.52](/filings/0000950170-25-064975.md) | [0.48](/filings/0000950170-25-103522.md) | [0.48](/filings/0001193125-25-265688.md) | not reported | [0.40](/filings/0000950170-25-064975.md) | [0.43](/filings/0000950170-25-103522.md) | [0.43](/filings/0001193125-25-265688.md) | not reported | not reported | not reported |

- Operating income: not reported
- Interest expense: us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [3.4](/filings/0001213900-23-085238.md) | [2.1](/filings/0000950170-25-028337.md) | [8.3](/filings/0001213900-24-040236.md) | [14.8](/filings/0001213900-24-066323.md) | [1.8](/filings/0000950170-24-121066.md) | [2.8](/filings/0001193125-26-073362.md) | [2.9](/filings/0000950170-25-064975.md) | [16.4](/filings/0000950170-25-103522.md) | [4.2](/filings/0001193125-25-265688.md) | [3.2](/filings/0001193125-26-333791.md) | [1.5](/filings/0001193125-26-207523.md) | [2.4](/filings/0001193125-26-333791.md) |
| Total assets | $m | [1,125](/filings/0001213900-23-085238.md) | [1,122](/filings/0000950170-25-028337.md) | [1,413](/filings/0001213900-24-040236.md) | [1,459](/filings/0001213900-24-066323.md) | [1,414](/filings/0000950170-24-121066.md) | [1,431](/filings/0001193125-26-073362.md) | [1,363](/filings/0000950170-25-064975.md) | [1,315](/filings/0000950170-25-103522.md) | [1,282](/filings/0001193125-25-265688.md) | [1,219](/filings/0001193125-26-333791.md) | [1,166](/filings/0001193125-26-207523.md) | [1,133](/filings/0001193125-26-333791.md) |
| Total liabilities | $m | [678](/filings/0001213900-23-085238.md) | [660](/filings/0000950170-25-028337.md) | [854](/filings/0001213900-24-040236.md) | [910](/filings/0001213900-24-066323.md) | [872](/filings/0000950170-24-121066.md) | [893](/filings/0001193125-26-073362.md) | [847](/filings/0000950170-25-064975.md) | [810](/filings/0000950170-25-103522.md) | [791](/filings/0001193125-25-265688.md) | [755](/filings/0001193125-26-333791.md) | [752](/filings/0001193125-26-207523.md) | [726](/filings/0001193125-26-333791.md) |
| Shareholders' equity | $m | [447](/filings/0000950170-24-121066.md) | [462](/filings/0001193125-26-073362.md) | [559](/filings/0000950170-25-103522.md) | [549](/filings/0001193125-25-265688.md) | [542](/filings/0001193125-25-265688.md) | [538](/filings/0001193125-26-333791.md) | [516](/filings/0001193125-26-333791.md) | [505](/filings/0001193125-26-333791.md) | [490](/filings/0001193125-25-265688.md) | [464](/filings/0001193125-26-333791.md) | [414](/filings/0001193125-26-333791.md) | [406](/filings/0001193125-26-333791.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(1.9) d](/filings/0000950170-24-121066.md) | [3.4 d](/filings/0001193125-26-073362.md) | [(238)](/filings/0000950170-25-064975.md) | [(0.5) d](/filings/0000950170-25-103522.md) | [3.5 d](/filings/0001193125-25-265688.md) | [34.3 d](/filings/0001193125-26-073362.md) | [46.4](/filings/0001193125-26-207523.md) | [41.0 d](/filings/0001193125-26-333791.md) | [17.5 d](/filings/0001193125-25-265688.md) | [55.7 d](/filings/0001193125-26-073362.md) | [29.1](/filings/0001193125-26-207523.md) | [21.3 d](/filings/0001193125-26-333791.md) |
| Share repurchases | $m | not reported | [0.0 d](/filings/0001193125-26-073362.md) | [0.0](/filings/0000950170-25-064975.md) | [0.3 d](/filings/0000950170-25-103522.md) | [0.2 d](/filings/0001193125-25-265688.md) | [0.8 d](/filings/0001193125-26-073362.md) | [1.5](/filings/0001193125-26-207523.md) | [4.2 d](/filings/0001193125-26-333791.md) | [4.7 d](/filings/0001193125-25-265688.md) | [7.6 d](/filings/0001193125-26-073362.md) | [1.6](/filings/0001193125-26-207523.md) | [4.1 d](/filings/0001193125-26-333791.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [23.2](/filings/0001213900-23-085238.md) | [24.6](/filings/0001213900-24-040236.md) | [25.5](/filings/0001213900-24-066323.md) | [26.0](/filings/0000950170-24-121066.md) | [31.6](/filings/0000950170-25-064975.md) | [32.6](/filings/0000950170-25-103522.md) | [32.6](/filings/0001193125-25-265688.md) | [32.6](/filings/0001193125-26-207523.md) | [32.3](/filings/0001193125-26-333791.md) | [32.1](/filings/0001193125-25-265688.md) | [31.2](/filings/0001193125-26-207523.md) | [31.0](/filings/0001193125-26-333791.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 30,651,221 at 2026-08-04, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-333791.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.